Abstract 3457
Background
With immunotherapy (IO) being the standard of care in melanoma, over time this has led to pressures within the medical day unit (MDU), especially as other cancer algorithms have evolved incorporating IO. Main pressures include reduced capacity, increasing patient numbers leading to greater pressure on doctors and requiring greater consultation time with patients to discuss survivorship issues. To help address these issues a pharmacist and nurse (P/N) led clinic was created as a new model of care in 2017.
Methods
Melanoma patients prescribed IO are placed into the clinic and reviewed 2-4 weekly as per IO regimen. Doctors review patients 12 weekly in outpatients for scan results. To assess the benefit of the clinic the number of referrals made back to the doctor before 12 weeks were recorded. Consultations needing >10 mins to discuss survivorships issues and P/N interventions were recorded.
Results
36 patients (age 24-89 yrs) have been referred to the clinic; 33 needed IO treatment, 2 steroid weaning and 1 temozolomide patient, needing nursing support. All patients required clinical evaluation for consideration of next cycle. Doctor’s input was required for 4 patients; 2 for inpatient admission for IO toxicity (monitoring for adrenal insufficiency, diabetic ketoacidosis), 1 for a biopsy (new skin nodule), 1 (scan results). Interventions routinely made by P/N included referrals to surgeons (3), dermatologist (2), ophthalmologist (2), tissue viability nurse (2), lymphedema team (2), physiological support (2) and fitness instructor (2). All patients required survivorship support and consultations ranged from 15-45 min. Common themes which emerged included how to partake in physical activity, anxiety on stopping IO, financial burden and advice on complementary therapies. In the melanoma team patients stop IO at 2yrs. Discussion on stopping IO is explored within 3 months of stopping IO; this discussion has occurred in 18/33 patients, in which the P/N helped alleviate patient’s anxiety over this time.
Conclusions
The clinic has become embedded within the melanoma service and has helped improve MDU pressures by removing patients requiring greater holistic support. This clinic in turn has sought out survivorship issues important to melanoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract